Ex Vivo Treatment with a Novel Synthetic Aminoglycoside NB54 in Primary Fibroblasts from Rett Syndrome Patients Suppresses MECP2 Nonsense Mutations

Samankaltaisia teoksia

• Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model
  Tekijä: Brendel, Cornelia, et al.
  Julkaistu: (2010)
• Erratum to: Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model
  Tekijä: Brendel, Cornelia, et al.
  Julkaistu: (2013)
• Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations
  Tekijä: Nudelman, Igor, et al.
  Julkaistu: (2009)
• Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54
  Tekijä: Rowe, Steven M., et al.
  Julkaistu: (2011)
• A comparative evaluation of NB30, NB54 and PTC124 in translational read-through efficacy for treatment of an USH1C nonsense mutation
  Tekijä: Goldmann, Tobias, et al.
  Julkaistu: (2012)